A new technology for shaping, tightening and sealing tissues for the aesthetic and medical markets.

Continuation Investments Ltd (ASX:COT) to be renamed The BioFusionary Corporation

www.biofusionary.com
Business Highlights

- TBC has developed and patented a proprietary high frequency electro-magnetic induction technology for shaping, tightening and sealing tissues for the multi-billion dollar aesthetic and medical markets.

- **FDA clearance** received for the technology March 2014. The BioFusionary Bebe™ system is indicated by the US FDA to be used to generate deep heat within body tissues for the treatment of medical conditions such as relief of pain, muscle spasms, and joint contractures but not for the treatment of malignancies.
  - *Dermal heating in the aesthetic market provides the first commercial application*

- Proprietary technology platform is planned to be applied to unmet medical needs and large markets including incontinence, surgical seals and adhesives.

- Experienced and successful executive team with strong track record in **patent generation and registration, regulatory approvals and sales and marketing**

- **IPO of TBC to launch the commercialization of BioFusionary Bebe**
Shaping, Tightening and Sealing

Aesthetics Now

Therapeutic Market

Sealing Post Surgery (Lung, Liver, Kidney, Dura, Peritoneal)

Incontinence, Full Functionality Restored
### Acquisition Terms

#### Indicative Capital Structure

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Current COT Shares:</td>
<td>19,865,377</td>
</tr>
<tr>
<td><strong>TBC Acquisition:</strong></td>
<td>100,000,000</td>
</tr>
<tr>
<td>Prospectus:</td>
<td>25,000,000</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>144,865,377</strong></td>
</tr>
</tbody>
</table>

#### Indicative Timeline

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholder Meeting:</td>
<td>18 September</td>
</tr>
<tr>
<td>Suspension from Trading:</td>
<td>18 September</td>
</tr>
<tr>
<td>Lodgement of Prospectus:</td>
<td>8 September</td>
</tr>
<tr>
<td>Offer Close:</td>
<td>6 October</td>
</tr>
</tbody>
</table>

#### Notes:

1. Assumes a prospectus capital raising of $5m at $0.20
2. 4.25m options (2.25m: $0.20, December, 2015; 2.0m: $0.30, October 2017)
## Proposed Board

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Biography</th>
</tr>
</thead>
</table>
| Damon R Cox       | Managing Director      | • Expert in medical industry product commercialization  
                           • Held several executive-level industry positions and previously launched multiple medical device, diagnostic and biopharma products. Past employment includes Allergan, Merz and Johnson & Johnson                                      |
| Dr Kevin Marchitto, PhD | Chief Scientific Officer | • Co-inventor of technology and founder of TBC  
                           • Biochemist with many registered patents  
                           • Management positions in research and product development at various biomedical companies  
                           • Served as Honorary Professor at Monash University  
                           • Led technology transfer efforts at various US health and science universities |
| Jeremy King       | Non-executive          | • 20+ years corporate and M&A lawyer specializing in cross border securities and debt financings in Europe and North America  
                           • Partner Grange Consulting, ASX company director                                                                                                                                          |
| TBA               | Non executive(s)       | At least one Independent Australian-based director with strong industry experience, emerging company management |
## TBC Products and Markets

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Application</th>
<th>Result</th>
<th>Status</th>
<th>Market Size (US)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>Rejuvenation, Skin Tightening</td>
<td>Clinical Tightening</td>
<td>Post-clinical</td>
<td>US$3.7bn</td>
</tr>
<tr>
<td>Muscle, Ligaments</td>
<td>Incontinence</td>
<td>Full Functionality</td>
<td>Pre-clinical</td>
<td>&gt;US$5bn</td>
</tr>
<tr>
<td>Cartilage</td>
<td>Joint Reconstruction, Restore Airway Passages</td>
<td>Re-shaped Tissue</td>
<td>Pre-clinical</td>
<td>&gt;US$5bn</td>
</tr>
<tr>
<td>Soft Tissue: Lung, Liver, Kidney</td>
<td>Sealing Post-Surgery</td>
<td>75-100% Efficacy</td>
<td>Animal Surgeries</td>
<td>US$10bn</td>
</tr>
</tbody>
</table>
The Aesthetic Market

- Expenditures on aesthetic minimally invasive procedures reached US$12.2 billion in 2013\(^1\). 13% growth in 2013\(^1\).
- Approximately 13,000 dermatologists in the US: gatekeepers to the skin rejuvenation market.
- Over 23,000 aesthetic practitioners also servicing the market.
- Recent US healthcare reform expected to significantly increase aesthetic practitioners.

Ulthera, an energy-based skin tightening device company, was acquired by Merz Pharma in July 2014 for US$600m.

1. American Society of Plastic Surgeons
US Skin Rejuvenation Market: $3.7bn

Source: American Society Plastic Surgeons (2012)
Existing Energy-powered Devices in the Aesthetics Market

- Radio Frequency (RF)
- Lasers & IPL
- Ultrasound
Basic Problem: Energy is Delivered Perpendicular to the Surface of the Skin

Results can include:
- Uneven heating
- Burns
- Poor tightening
- Weak Seals

Lasers & Ultrasound

Radiofrequency
The BioFusionary Bebe: Generates Heat *Internally*, Parallel to the Surface

**Result:**
- Uniform heating
- No tissue damage
- Great tightening
- Strong Seals
The BioFusionary Bebe: Desired Efficacy With Minimal Side Effects

Patient Advantage:
• Dramatic tightening efficacy
• No adverse events, no down time
• Nearly pain-free

Physician Advantage:
• Short procedures save time
• Subjects often request additional treatments
• Broader treatment options (age and location)
The BioFusionary Bebe: Development Timeline

Phase 1
R & D

Phase 2
Regulatory Review

Phase 3
Commercialisation

Phase 4
Market Penetration

Current Status – August 2014

- March 2014 FDA Clearance
- Sep- Dec 2014 Targeted US Launch

2015 Global Launch
### Aesthetic Market - Recent Transactions

<table>
<thead>
<tr>
<th>Company</th>
<th>Acquiror / Public</th>
<th>Amount / IPO</th>
<th>Year</th>
<th>Market Cap Now</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOLTA MEDICAL</td>
<td>VALEANT</td>
<td>$US250 M</td>
<td>2014</td>
<td>-</td>
</tr>
<tr>
<td>thermage</td>
<td></td>
<td>$US42 M</td>
<td>2012</td>
<td>-</td>
</tr>
<tr>
<td>coolsculpting</td>
<td></td>
<td>$US115 M</td>
<td>2012</td>
<td>$US723 M</td>
</tr>
<tr>
<td>IPO (Zeltiq)</td>
<td></td>
<td>$US65 M</td>
<td>2010</td>
<td>$US344 M</td>
</tr>
<tr>
<td>ulthera</td>
<td>MERZ</td>
<td>$US600 M</td>
<td>2014</td>
<td>-</td>
</tr>
</tbody>
</table>
Technology Platform: A Product Pipeline

**Muscle and Tissue Manipulation:**

- **Incontinence:** Pre-clinical studies have generated sufficient evidence of an effective treatment of incontinence utilising the BioFusionary technology.

- **Cartilage Reshaping:** The technology has been shown to reshape cartilage, with significant opportunities for airway blockage (trachea), ear and nose reconstruction and knees, shoulders and other joints.

![Image A is a pig ear prior to treatment and image B is the same ear after treatment.](image)

Tracheal tissue (A and C) were cut, inverted and treated through induction heating. Panels B and D show that the cartilaginous tissue could be reformed “inside-out”, providing evidence that tracheal cartilage can be reshaped in the body to open up airways.
Adhesives:

- Adhesives based on BioFusionary technology are a radical new concept – the first curable synthetic medical adhesive based on elastic polymers.

- No available medical adhesive product performs like the BioFusionary adhesive – cured using its proprietary EMI technology, with seals forming under pressure or while blood spills over a wound.
<table>
<thead>
<tr>
<th>Department</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marketing and Sales</td>
<td>2,100,000</td>
</tr>
<tr>
<td>Manufacturing</td>
<td>2,435,000</td>
</tr>
<tr>
<td>Prototyping, Research and Development</td>
<td>500,000</td>
</tr>
<tr>
<td>Administrative and Facilities</td>
<td>620,000</td>
</tr>
<tr>
<td>Regulatory and Clinical</td>
<td>225,000</td>
</tr>
<tr>
<td>Intellectual Property &amp; Legal</td>
<td>120,000</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>$6,000,000</strong></td>
</tr>
</tbody>
</table>
Peer Review

- **National Institute of Health (NIH) Reviewers:**

  “The investigators are pioneers in this area of research.

  “Highly innovative approach ...without precedent in the medical literature.

  “In some surgical applications, the BioFusionary product would eventually replace sutures and staples”

- **Trials of the BioFusionary Bebe have been strongly endorsed by prominent US medical practitioners as both highly effective and safe**
“Look Better, Feel Great™”

Irene, 70 years.

Tina, 74 years.
Forward Looking Statements

This information includes "forward-looking statements" of The BioFusionary Corporation ("BioFusionary") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this information that address activities, events or developments that BioFusionary believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors BioFusionary believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of BioFusionary. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to obtain FDA clearance or approval, obtain CE Marking, cost effectively manufacture and generate revenues from the at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the BioFusionary Bebe™ management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, BioFusionary does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this information should be considered in conjunction with the risk factors contained in our private placement memorandum dated.